VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
BCLI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
BCLIBrainstorm Cell Therapeutics Inc.
$0.90$10M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
BCLI logo

Brainstorm Cell Therapeutics Inc.

BCLI
NASDAQ · Cell & Gene Therapy
$0.90
At close - Nov 18, 4:00 PM EST - USD
Market Cap$10M
P/E-0.8x
52W High$1.69
Volume2.5K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Revenue Absence Signals Imminent Insolvency Risk

Brainstorm Cell Therapeutics remains in a precarious pre-commercial state, characterized by nine consecutive quarters of zero revenue and an accelerating erosion of its financial foundation.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsMixed
Explore valuation models
MARKET ACTION

BCLI price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-102% Peers

P/E is 102% below peer median

03

Market leadership

RS 83 · Leader

High momentum (Outperforming 83% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Feb 16

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
BCLI+47.38%
S&P 500 (^GSPC)+6.88%
1-Year Return
BCLI+45.00%
S&P 500 (^GSPC)+10.62%
3-Year Return
BCLI-66.70%
S&P 500 (^GSPC)+62.67%
5-Year Return
BCLI-98.00%
S&P 500 (^GSPC)+62.24%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-0.8x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-0.8x
1.0x
0th· Low
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$10M-188.7% YoY
Free cash flow FY25
-$7M+23.3% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-493.8%
ROE (FY25)-
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
-$0.14+22.2%
vs -$0.18
—
vs —
Q3 2026
Aug 14, 2026
-$0.35-20.7%
vs -$0.29
—
vs —
Q2 2026
May 15, 2026
-$0.19+47.2%
vs -$0.36
—
vs —
Q2 2026
Mar 31, 2026
-$0.19+32.1%
vs -$0.28
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

2 Stories
PRNewsWire·2d ago
BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update. "ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.

PRNewsWire·Aug 24, 2026
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.

Filtered for Brainstorm Cell Therapeutics Inc.More Headlines
04

Compare before deciding

Benchmark BCLI against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Brainstorm Cell Therapeutics Inc. (BCLI)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
BCLI logoBCLIBrainstorm Cell Therapeutics Inc.Current
$0.90$9.92M-0.81————
CLLS logoCLLSCellectis S.A.
$1.03$103.43M-1.5975.76%-115.48%-94.24%—
FATE logoFATEFate Therapeutics, Inc.
$1.05$122.39M-1.04-51.24%-2619.64%-73.92%—
AGEN logoAGENAgenus Inc.
$6.40$266.51M18.9710.37%20.98%——
NKTR logoNKTRNektar Therapeutics
$34.42$1.18B-6.64-43.89%-339.67%-29.31%—
SNGX logoSNGXSoligenix, Inc.
$0.25$3.75M-0.63——-165.88%—

Compare BCLI vs Peers

Brainstorm Cell Therapeutics Inc. (BCLI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CLLS

Most directly comparable listed peer for BCLI.

Scale Benchmark

vs TMO

Larger-name benchmark to compare BCLI against a more recognizable public peer.

Peer Set

Compare Top 5

vs CLLS, FATE, AGEN, NKTR

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

BCLI SEC Filings & Documents

Brainstorm Cell Therapeutics Inc. (BCLI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 14, 2026·SEC

Material company update

Jul 30, 2026·SEC

Material company update

May 28, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 14, 2026·SEC

FY 2026

May 15, 2026·SEC

FY 2025

Nov 14, 2025·SEC

Get notified when BCLI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BCLI Frequently Asked Questions

Brainstorm Cell Therapeutics Inc. (BCLI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is BCLI profitable?

No. Brainstorm Cell Therapeutics Inc. (BCLI) reported a net loss of $10.1M over the trailing twelve months.

Dividend & Returns
What is Brainstorm Cell Therapeutics Inc.'s free cash flow?

Brainstorm Cell Therapeutics Inc. (BCLI) had negative free cash flow of $3.7M over the trailing twelve months.

What if you invested $1,000 in BCLI back in 2001?

Total return calculator · dividends reinvested · 25+ years of data

See returns →